Salicylic-acid creams and alternatives
Read the record behind the product.
The same ingredient number can appear on different product records. Read identity, evidence, transaction and unresolved detail together before treating those records as equivalent.
Open the comparison records →Eight original articles trace the public descriptions and the questions those descriptions leave open.
Three names.
Different records.
CoreAge receives first commercial placement here. That order does not establish a clinical advantage or make these formats equivalent.
Provider review
Pore Favor formula review: the information behind the prescription offer
Read the advertised concentrations, compounded status, care process and full plan charges as separate records.
Provider review
The Ordinary Salicylic Acid 2% Solution: a four-pass review
The exact US solution has a visible bottle offer and active-ingredient panel, plus wording that needs clarification.
Provider review
CeraVe Acne Control Cleanser: the label and the current page
A precise acne-cleanser identity, an OTC monograph record and an unresolved ingredient-version difference.
The disclosed commercial shortlist
Salicylic-acid creams and alternatives: records worth comparing
A commercially disclosed cream feature alongside two explicitly different retail formats.
A way to read the paperwork
Four records worth keeping separate.
The complete name identifies the comparison
These names and formats establish what the pages describe. They do not show that an individual package has been inspected or that the products can replace one another in a care plan.
Read the fact and unresolved detail →A matching strength leaves other fields open
A matching percentage does not demonstrate equal finished-product exposure, performance or tolerance. Ingredient guidance from AAD does not supply a head-to-head study of these three preparations.
Read the fact and unresolved detail →A regulatory category is not an endorsement
Prescription access, OTC availability and individual approval are different concepts. FDA also states that an NDC listing does not establish approval or verification of the submitted product information.
Read the fact and unresolved detail →The term belongs beside the displayed price
These observations describe an offer, not a completed charge or the physical quantity supplied. A commercial term does not establish how long an individual should receive treatment or when clinical follow-up should occur.
Read the fact and unresolved detail →Evidence guides
What the headline leaves out.
Guide
Two products say 2% salicylic acid: what actually matches?
A strength description is one field in a comparison, not a finding of equal formulation, exposure or results.
Guide
Compounded salicylic cream and retail acne products: three records to keep separate
Prescription access, an OTC label and individual product approval are not interchangeable descriptions.
Guide
A year-plan price is not a year-long treatment instruction
Read the actual Pore Favor totals, the monthly displays and the supply questions that a plan name leaves unanswered.
Guide
Which salicylic product does this label describe?
Brand name, formulation version, package and publication date need to remain connected when records differ.
A strength, a regulatory category and a plan price answer different questions. Read how this publication treats the evidence.